Between the Biotech Waves

Episode 24: A Between the Biotech Waves conversation with John Hoffman, managing director & head of healthcare equity capital markets at Credit Suisse

Jan 8, 2023
Ask episode
Chapters
Transcript
Episode notes
1
Introduction
00:00 • 2min
2
The Depressing Future of Biotech
01:33 • 3min
3
The Learning Trauma of 2022
04:58 • 4min
4
The Resilience of the IPO Market
09:22 • 2min
5
Biotech and Equity Alternatives: A Good Place to Be
11:17 • 3min
6
The Ecosystem of Biotech
14:47 • 2min
7
The Green Flags of a Potential M&A Market
16:21 • 5min
8
The Impact of M&A on the Bottom Line
21:01 • 2min
9
The Impact of Capital Redeployment on the Biotech Sector
23:30 • 2min
10
The Short Overhang in the XDI Sector
25:20 • 4min
11
The Path to Financing in 2023
28:58 • 4min
12
The Importance of Preparing for a Triangle IPO
33:25 • 3min
13
The Importance of Pricing in an IPO
36:09 • 2min
14
The Impact of the Inflation Reduction Act on the Private Market
38:18 • 5min
15
The Signal of a Robust Financing Environment for Biotech
43:07 • 2min
16
The Reverse of the Biotech Sector
45:35 • 2min
17
The Importance of Body Language in the IPO Market
47:24 • 3min
18
Between the Biotech Waves
50:00 • 2min